IL12B gene polymorphisms have sex-specific effects in relapsing–remitting multiple sclerosis

[1]  J. Bienertová-Vašků,et al.  Association of interleukin 6, interleukin 7 receptor alpha, and interleukin 12B gene polymorphisms with multiple sclerosis , 2018, Acta Neurologica Belgica.

[2]  S. Sánchez-Ramón,et al.  Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients , 2018, Front. Immunol..

[3]  A. Jafarzadeh,et al.  Association of Interleukin-12B Gene Polymorphism With Multiple Sclerosis in Patients From Southeast of Iran , 2018 .

[4]  S. Bonin,et al.  Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy , 2018, Immunological investigations.

[5]  A. Rizvanov,et al.  Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients , 2017, Front. Immunol..

[6]  Anastasiya G. Trenova,et al.  Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis , 2017, Scandinavian journal of clinical and laboratory investigation.

[7]  Arash Salmaninejad,et al.  An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis , 2017, Neurological research.

[8]  Burkhard Becher,et al.  Cytokine networks in neuroinflammation , 2016, Nature Reviews Immunology.

[9]  Ying Kuang,et al.  Meta-analysis of the IL23R and IL12B polymorphisms in multiple sclerosis , 2016, The International journal of neuroscience.

[10]  C. Egwuagu,et al.  Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. , 2015, Cytokine.

[11]  Pierre Grammond,et al.  Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS , 2015, PloS one.

[12]  M. Etemadifar,et al.  IL-23 Plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects , 2015, Immunological investigations.

[13]  A. Achiron,et al.  Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome , 2014, Multiple sclerosis.

[14]  D. Reich,et al.  Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation , 2012, PloS one.

[15]  M. Reale,et al.  Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients , 2012, International journal of molecular sciences.

[16]  G. Jiang,et al.  Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis , 2012, Journal of Neuroimmunology.

[17]  C. Baecher-Allan,et al.  Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease , 2011, Nature Medicine.

[18]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[19]  Yuhong Yang,et al.  Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? , 2011, Biochimica et biophysica acta.

[20]  L. Miteva,et al.  Association of Polymorphisms in Regulatory Regions of Interleukin-12p40 Gene and Cytokine Serum Level with Colorectal Cancer , 2009, Cancer investigation.

[21]  L. Miteva,et al.  The influence of JNK and P38 MAPK inhibition on IL-12P40 and IL-23 production depending on IL12B promoter polymorphism , 2009, Cellular & Molecular Biology Letters.

[22]  N. Rezaei,et al.  IL-2, IFN-γ, and IL-12 Gene Polymorphisms and Susceptibility to Multiple Sclerosis , 2009, Journal of Clinical Immunology.

[23]  M. Racke,et al.  Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? , 2009, Expert review of neurotherapeutics.

[24]  K. Pahan,et al.  IL-12 p40 homodimer, but not IL-12 p70, induces the expression of IL-16 in microglia and macrophages. , 2009, Molecular immunology.

[25]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[26]  P. Ragonese,et al.  Search for Genetic Factors Associated with Susceptibility to Multiple Sclerosis , 2006, Annals of the New York Academy of Sciences.

[27]  L. Miteva,et al.  Taq-I polymorphism in 3′UTR of the IL-12B and association with IL-12p40 production from human PBMC , 2005, Genes and Immunity.

[28]  Jie Xiong,et al.  Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs , 2005, Cell Research.

[29]  Lin He,et al.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci , 2005, Cell Research.

[30]  Subhajit Dasgupta,et al.  Induction of tumor necrosis factor‐α (TNF‐α) by interleukin‐12 p40 monomer and homodimer in microglia and macrophages , 2003 .

[31]  C. Polman,et al.  Interleukin‐12p40 genotype plays a role in the susceptibility to multiple sclerosis , 2001, Annals of Neurology.

[32]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[33]  M. Gulubova,et al.  Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus , 2010, Rheumatology International.

[34]  R. Bergamaschi.  Prognostic factors in multiple sclerosis. , 2007, International review of neurobiology.

[35]  R. N. Saha,et al.  Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. , 2003, Journal of neurochemistry.